VYNE Therapeutics Inc. (VYNE) Dividend History

VYNE Therapeutics Inc. is a biopharmaceutical company focused on developing innovative, prescription-based therapies for dermatologic conditions. Founded with the goal of addressing underserved skin diseases, VYNE leverages proprietary formulations and technologies to create targeted treatments. The company’s portfolio includes products aimed at conditions such as atopic dermatitis and other inflammatory skin disorders.

685 Route 202/206 N., Suite 301, Bridgewater, NJ, 08807
Phone: 800-775-7936
Website: https://www.vynetherapeutics.com

Dividend History

VYNE Therapeutics Inc. currently does not pay dividends

Company News

  • VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

    Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases

    GlobeNewswire Inc.
  • Analyst Scoreboard: 4 Ratings For VYNE Therapeutics

    Across the recent three months, 4 analysts have shared their insights on VYNE Therapeutics (NASDAQ:VYNE), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $5.75, a high estimate of $5.75, and a low estimate of $5.75. Holding firm without variation, the current average remains at the previous average price target. Decoding Analyst Ratings: A Detailed Look In examining recent analyst actions, we gain insights into how financial experts perceive VYNE Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Pantginis HC Wainwright & Co. Maintains Buy $5.75 $5.75 Joseph Pantginis HC Wainwright & Co. Maintains Buy $5.75 $5.75 Joseph Pantginis HC Wainwright & Co. Maintains Buy $5.75 $5.75 Joseph Pantginis HC Wainwright & Co. Maintains Buy $5.75 $5.75 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to VYNE Therapeutics. This information offers a snapshot of how analysts perceive ...Full story available on Benzinga.com

    Benzinga
  • VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

    VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: HROW
  • 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560%

    Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: ENSC MYPS OCGN
  • VYNE Therapeutics Inc. (VYNE) Q2 2021 Earnings Call Transcript

    VYNE earnings call for the period ending June 30, 2021.

    The Motley Fool
Page data last updated 07/23/2025 21:31:29 UTC